Home Events PD-L1 testing in H&N cancer: The Canadian Experience – Presented by Merck

PD-L1 testing in H&N cancer: The Canadian Experience – Presented by Merck

Date

March 31 2021

Time

1:00 pm - 2:30 pm

Speakers

  • Dr Bayardo Perez-Ordonez
    Dr Bayardo Perez-Ordonez

    Dr. Bayardo Perez-Ordonez is a pathologist at the University Health Network (UHN), Division of Anatomic Pathology, Laboratory Medicine Program, and associate professor at the University of Toronto. After attending medical school at the National Autonomous University of Nicaragua, he completed his anatomic pathology residency at St. Louis University, St. Louis (MO) and at the University of Toronto. He then completed his fellowship in oncologic surgical pathology and head and neck pathology at the Memorial Sloan-Kettering Cancer Center, New York.

  • Dr Lillian Siu
    Dr Lillian Siu

    Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre, and holds the BMO Chair in Precision Genomics (2016-2026). Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies.

Description:

This session will review the research behind the rationale for PD-L1 testing in unresectable recurrent and metastatic head and neck cancer from a perspective of a medical oncologist and a pathologist.

Objectives:

  • Provide an overview of the pathologist’s role in unresectable recurrent and metastatic HNSCC (uR/M HNSCC)
  • Review the rationale and evolution of PD-L1 CPS testing in uR/M HNSCC
  • Discuss how samples are processed for testing and interpretation

This content is restricted to subscribers

Register

Presented by